Overview

FAAH Availability in Psychiatric Disorders: A PET Study

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:
0

Participant gender:
All

Summary

The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system are observed.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Yale University

Criteria

Inclusion Criteria:

- Between the ages of 18 and 65 years, inclusive

- Good physical health as determined by history, physical and laboratory examinations,
ECG, and vital signs

PTSD Inclusion Criteria:

- Diagnosis of Post-Traumatic Stress Disorder

AUD Inclusion Criteria:

- Diagnosis of Alcohol Use Disorder

Psychosis Inclusion Criteria:

- Diagnosis of psychotic disorder such as Schizophrenia, Schizoaffective disorder

Exclusion Criteria:

- Presence of ferromagnetic metal in the body or heart pacemaker

- Women with a positive pregnancy test or women who are lactating